Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

breakthrough therapy

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

Novartis building

Novartis says pipeline is “industry leading”

Touts 14 drug candidates with $1bn-plus sales potential

Novartis building

Novartis’ heart failure drug serelaxin meets targets

And FDA committee backs Signifor for Cushing's disease

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

Novartis building

EC approves extra tumour indication for Novartis’ Votubia

First drug approved in Europe for non-cancer tumours associated with TSC

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

Novartis building

Canada and Switzerland lift Novartis flu vaccines ban

Independent tests confirm safety following contamination fears

- PMLiVE

Novartis revives delayed Singapore biotech plans

Aims to have biotechnology facility up and running before 2017

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

GSK, Pfizer and Shionogi rewrite HIV joint venture terms

Comes ahead of first regulatory submissions for lead drug candidate dolutegravir

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links